A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07476118
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Brenipatide — DRUG
    Administered SC.
  • Placebo — OTHER
    Administered SC.

Study Details

The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will last about 42 weeks.

Key Dates

First listed
Mar 17, 2026
Start date
Mar 18, 2026
Status verified
Jul 2026
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Brenipatide
    Participants will receive brenipatide subcutaneously (SC).
  • Placebo Comparator: Placebo
    Participants will receive placebo administered SC.

Primary Outcome Measure

Percent Change in Body Weight [ Time Frame: Week 1, Week 29 ]

Locations (3)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit - Daytona BeachDaytona BeachFlorida32117-5116-
Fortrea Clinical Research UnitDallasTexas75247-
Fortrea Clinical Research Unit Inc. - MadisonMadisonWisconsin53704-

Find similar trials in Daytona Beach, FL

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Fortrea Clinical Research Unit - Daytona Beach· Daytona Beach, FLFortrea Clinical Research Unit· Dallas, TXFortrea Clinical Research Unit Inc. - Madison· Madison, WI

Related Studies